A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patel, Nilesh K.
- Stability testing: An Essential study for Vaccine Formulation Development
Authors
1 B. K. Mody Government Pharmacy College, Rajkot-360003, Gujarat, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 1 (2022), Pagination: 29 - 36Abstract
Forced degradation studies are carried out at a more severe condition than accelerated conditions. Stress studies for vaccines are carried out in the early stage of development. By conducting stress studies, we can know the chemical behavior of our molecule which is important while developing formulation, packaging, transportation, storage, etc. there are general regulatory guidelines are available for conducting forced degradation studies but there is no sufficient information provided about how to perform forced degradation studies. Thus, this review discussed stress testing studies of vaccines, mechanisms of vaccine degradation, also analytical methods which are helpful to develop a method for forced degradation.
Keywords
Vaccine, Stability testing of the vaccine, Forced degradation, Analytical Methods, Degradation MechanismReferences
- Rashmimala Pradhan. Effectiveness of Information Booklet on Immunization among GNM 1st Year Students in a Selected Nursing School at Bhubaneswar, Odisha. Asian J. Nur. Edu. and Research. 2015; 5(1): 64-66.
- Saraswathi. K.N, Lissa J. A study to assess the knowledge on selected optional vaccines among mothers of under-five children in selected immunization centers at Mysore with the view to developing an information booklet. Asian J. Nur. Edu. and Research. 2014; 4(4): 513-515
- Blessy M, Patel R, Prajapati P, Agrawal Y. Development of forced degradation and stability indicating studies of drugs—A review. Asain Journal of Pharmaceutical Analysis. 2013; 4(3): 159-165.
- Patel P . U., Prajapati A.M., Patel M.M. Development and validation of analytical methods for estimation of Levosimendan in the injectable dosage form. Research J. Pharm. and Tech. 2012;5(12): 1543-1548.
- Vysakh Visweswaran, Ameya Binoy, Anjana Sreenivas, B Abhinand, Meenu Vijayan. Vaccines-Pillars of Preventive Health. Research J. Pharm. and Tech. 2017; 10(9): 3205-3210.
- Ananya K V, Amit B Patil, D V Gowda, Preethi S. Adjuvants employed in the Fabrication of sublingual vaccines. Research J. Pharm. and Tech. 2020; 13(8): 3957-3962.
- Hasija M, Lillian L. Forced degradation studies: an essential tool for the formulation development of vaccines. J. Vaccine: Development and Therapy. 2013; 3: 11-33.
- Shubhangi V. Sutar, Veerendra. C. Yeligar, Shitalkumar S. Patil. Stability Indicating Forced Degradation Studies. Research J. Pharm. and Tech. 2019; 12(1): 429-433.
- Md. Jakaria, Md. Hazrat Ali, Md. Areeful Haque, Mohammed Abu Sayeed, Shoayeb Ahmed. In-vitro Comparative Forced Degradation Study of Different Brands and Active form of Montelukast sodium using UV Spectrophotometer. Asian J. Pharm. Ana. 2015; 5(1): 26-30.
- Parag A. Pathade, Vinod A. Bairagi, Yogesh S. Ahire, Bhaskar O. Aher. Development and Validation of Stability Indicating UV Spectrophotometric Method for Estimation of Teneligliptine in Bulk and Tablet Dosage Form. Asian J. Pharm. Ana. 2019; 9(3):128-132.
- Hawe A, Wiggenhorn M. Forced Degradation of Therapeutic Proteins” J. Journal of Pharmaceutical Sciences. 2012; 101(3): 895-913.
- Iram F, Iram H, Iqbal A, Husain A. Forced Degradation Studies. J. Journal of Analytical & Pharmaceutical Research. 2016; 3(6): 1-5.
- ICH – Harmonized Tripartite Guideline. Photostability Testing of New Drug Substances and Products Q1B. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline.Validation of Analytical Procedures: Text and Methodology. Q2(R1). International Conference on Harmonization IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Impurities in New Drug Substances. Q3A(R2). International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Impurities in New Drug Products. Q3B(R2). International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Stability Testing of Biotechnological/ Biological Products. Q5C. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products. Q6B. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Q8(R2). International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- ICH – Harmonized Tripartite Guideline. Development and Manufacture of Drug Substances Q11. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2005.
- WHO/KFDA Workshop on Stability Evaluation of Vaccines, Seoul, Republic of Korea 30 March 2009.
- Chan C. Forced degradation studies: current trends and future perspectives for protein-based therapeutics. J. Expert Review of Proteomics. 2016; 1744.
- Clapp T, Siebert P, Chen D, Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. Journal of Pharmaceutical Science. 2010; 100: 388-401.
- Patel K, Borchardt R. Chemical Pathways of Peptide Degradation. III. Effect of Primary Sequence on the Pathways of Deamidation of Asparaginyl Residues in Hexapeptides. J. Pharmaceutical Research. 1990; 7(7): 787–793.
- Chi E, Krishnan S, et al. Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation. J. Pharmaceutical Research. 2003; 20(9):1325–1336.
- Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ. Effect of Physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide -CRM (197) conjugate vaccines. J. Vaccine. 2000. D`1Qaq11`ZWS4
- Estey T, Vesely C, Randolph W, et al. Evaluation of chemical deg- radation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. Journal of Pharmaceutical Science. 2019; 98: 2994-3012.
- Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, Sidduri P. Forced degradation studies to assess the stability of drugs and products. J. Trends in Analytical Chemistry. 2013.
- Goldberg A. Protein degradation and protection against misfolded or damaged proteins. J. Nature. 2003; 426: 895–899.
- Majumdar S, Ford BM, Mar KD, et al. Evaluation of the effect of syringe surfaces on protein formulations. Journal of Pharmaceutical Sciences. 2011; 100: 2563–2573.
- kissmann J, Ausar SF, Rudolph A, et al. Stabilization of measles virus for vaccine formulation. J. Human Vaccine. 2008; 4(5): 50-359.
- Habig WH. Potency testing of bacterial vaccines for human use. J. Veterinary Microbiology. 1993; 37: 343-351.
- Poland GA, OvsyannikovaIG, Johnson KL, Naylor S. The role of mass spectrometry in vaccine development. J. Vaccine. 2001; 2692–2700.
- Ratliff T, Ritchey J, Brandhorst J, et al. Time-dependent aggregation of reconstituted BCG vaccine. The Journal of Urology. 1994; 152: 2147-2149.
- Krell T, Manin C, et al. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry. Biotechnol Appl Biochem. 2005; 241–246.
- Ausar F, Chan J, Hoque W, James O, Jayasundara K, Harper K. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. Journal of Pharmaceutical Science. 2011; 100: 431-440.
- Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm Sci. Epub. 2011.
- Chang S, Kendrick S, Carpenter F. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. Journal Pharmaceutical Science. 1996; 85(12): 1325–1330.
- Kolhe P, Badkar A. Protein and solute distribution in drug substance containers during frozen storage and post-thawing: a tool to understand and define freezing-thawing parameters in biotechnology process development. Biotechnol Prog. 2011; 27(2): 494–504.
- A Review on Prophylactic Regimen by Evaluation of Asymptomatic SARS CoV-II Carriers
Authors
1 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot, Gujarat, IN
2 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot, Gujarat, GG
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 3 (2022), Pagination: 217 - 224Abstract
The coronavirus disease 19(COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-II), which emerged in Wuhan, China and spread around the world. It is considered a relative of Severe Acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), The cause of COVID-19 is a beta coronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. The Asymptomatic carriers have become the current focus of global epidemic prevention and control efforts. These carriers of the virus display no clinical symptoms but are known to be contagious. As "silent spreaders", asymptomatic carriers warrant attention as a part of disease prevention and control. The comparable viral load in a group of asymptomatic carriers of COVID-19 was found to be higher than that of the symptomatic carriers. There are numerous micronutrients which are essential for immunocompetence, particularly Vitamin A, C, D, E, B, iron, selenium, and zinc. Immunonutrition refers to the modulation of the immune system through the modification of dietary nutrients. Vitamins A to E highlighted potentially beneficial roles in the fight against COVID-19 via antioxidant effects, immunomodulation, enhancing natural barriers, and local paracrine signaling. The present review provides a brief information on supplementation of Immunonutrients in form of vitamins which ultimately can act as prophylactic regimen for Asymptomatic carriers of SARS CoV-II virus.
Keywords
Asymptomatic carriers, SARS CoV-II, Covid-19, Immunonutrients, VitaminsReferences
- Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int. J. Infect. Dis 2016; 49:129–133.
- Vijayanand P, Wilkins ED, Woodhead M. Severe acute respiratory syndrome (SARS): A Review. Clin. Med 2004; 4(2): 152-160
- Sharma A, Mohanan K. Obstacles Faced by Nurses working in Covid-19 Unit: A Developing Country view Point. Asian J. Nursing Education and Research. 2020; 10(4):459-62.
- Fernanades M, Thakur JR, Gavanje MS. A study to assess knowledge regarding Covid-19 among nursing students. Asian Journal of Nursing Education and Research 2021; 11(1) :65-67.
- Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. Emerg Infect. Dis. 2006;12(12): 1834-40.
- JainMS, Barhate SD. Corona viruses are a family of viruses that range from the common cold to MERS corona virus: A Review. Asian J. Res. Pharm. Sci. 2020; 10(3):204-210
- Kishor SR, Ramhari BM. Introduction to Covid-19. Research J. Science and Tech. 2020; 12(4):338-45.
- Yadav AR, Mohite SK. A Review on Severe Acute Respiratory Infection (SARI) and its Clinical Management in Suspect/ Confirmed Novel Coronavirus (nCoV) Cases. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):178-180.
- Naresh BV. A review of the 2019 Novel Coronavirus (COVID 19) Pandemic. Asian J. Pharm. Res. 2020; 10(3): 233-8.
- Bergmann CC, Silverman RB. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. Cleveland Clinic Journal of Medicine 2020; 87(6): 321-7.
- Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect. Dis. 2020; 20(4): 410-11
- Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020: 323(14) :1406-7
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382: 1708-20
- Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan. China J Med Virol 2020; 92: 441–447
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395: 495-506.
- Lei. J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020; 295: 200-236.
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review. JAMA. 2020; 324(8):782-93.
- Iyer M, Jayaramayaa K, Subramaniam M, et al. COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep. 2020; 53(4): 191–205.
- Majumder MS, Mandl KD. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. Lancet Glob Health 2020; 8(5): 627-30
- Buheji M, Buheji AR. Designing Intelligent System for Stratification of COVID-19 Asymptomatic Patients. American Journal of Medicine and Medical Sciences 2020;10(4): 246-57
- Cohen E. Infected people without symptoms might be driving the spread of coronavirus more than we realized. CNN.com. 2020 https://edition.cnn.com/2020/03/14/health/coronavirus-asymptomatic-spread/index.html.
- Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet 2020; 395: 689-97.
- Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis 2020; 221(11):1757-61.
- Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Eng J Med 2020; 382:1708-20.
- Thakur S, Srivastava N.Nutraceuticals : A Review. Asian J. Res. Pharm. Sci. 2016; 6(2): 85-94.
- Soares ADN, Costa KA, Wanner SP, et al. Dietary glutamine prevents the loss of intestinal barrier function and attenuates the increase in core body temperature induced by acute heat exposure. Br. J. Nutr. 2014, 112(10), 1601–10.
- Gadge SS.Antiviral and Immunity-modulating Natural Herbs in the Prevention of COVID-19. Research Journal of Pharmacognosy and Phytochemistry. 2021; 13(2):81-4
- Derouiche S. Current Review on Herbal Pharmaceutical improve immune responses against COVID-19 infection. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):181-184.
- Sporn MB, Dunlop NM, Newton DL. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 1976; 35: 1332-8.
- Patel VK, Patel CK, Patel HU, et al. Vitamins, Minerals and Carotenoids as Antioxidants. Asian J. Research Chem. 2020; 3(2):255-260.
- Tanumihardjo SA. Vitamin A: Biomarkers of nutrition for development. Am. J. Clin. Nutr. 2011; 94 (2): 658S–65S.
- Senoo H, Yoshikawa K, Morii M, et. al. Hepatic stellate cell (vitamin A-storing cell) and its relative—Past, present and future. Cell Biol. Int. 2010; 34: 1247–1272.
- Retinol|C20H30O—PubChem. June 2021 available on https://pubchem.ncbi.nlm.nih.gov/compound/Retinol
- Paiva SAR, Godoy I, Vannucchi H, et al. Assessment of vitamin A status in chronic obstructive pulmonary disease patients and healthy smokers. Am. J. Clin. Nutr. 1996; 64: 928–34.
- Arora P, Kumar V, Batra S. Vitamin A status in children with asthma. Pediatr. Allergy Immunol. 2002; 13: 223–6.
- Green HN Mellanby E. Vitamin a as an anti-infective agent. Br. Med. J. 1928; 2: 691–6.
- European Union. EU Register on Nutrition and Health Claims 2020 available on https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/ public.
- Calder PC, Carr AC, Gombart AF, et al. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 2020; 12(4): 1181.
- Kishimoto K, Kobayashi R, Sano H, et al. Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption. Clin. Immunol. 2014; 153: 17–22.
- Vogiatzoglou A, Refsum H, Johnston C, et al. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology 2008; 71: 826–32.
- Serseg T, Benarous K, Yousfi M. Hispidin and lepidine E: Two natural compounds and folic acid as potential inhibitors of 2019- novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study. Curr. Comput. Aided. Drug Des. 2020.
- Padayatty SJ, Levine M. Vitamin C: The known and the unknown and Goldilocks. Oral Dis. 2016; 22: 463–93.
- Wang Y, Russo TA, Kwon O, et al. Ascorbate recycling in human neutrophils: Induction by bacteria. Proc. Natl. Acad. Sci. USA 1997; 94: 13816–19.
- Thomas WR, Holt PG. Vitamin C and immunity: An assessment of the evidence. Clin. Exp. Immunol. 1978; 32: 370–79.
- Webb AL, Villamor E. Update: Effects of antioxidant and non- antioxidant vitamin supplementation on immune function. Nutr. Rev. 2007; 65: 181–217.
- Ziegler HW, Sternsdorf T, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-_B mobilization and TNF production in human monocytes. J. Immunol. 1993; 151(12): 6986–993.
- Lo SK, Janakidevi K, Lai L, et al. Hydrogen peroxide-induced increase in endothelial adhesiveness is dependent on ICAM-1 activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 1993; 264: L406–L412.
- Senses H. Vitamin C Effective Against COVID-19: Expert; Anadolu Agency: Ankara, Turkey, 2020.
- Australian Government. No Evidence to Support Intravenous High-Dose Vitamin C in the Management of COVID-19; Therapeutic Goods Administration: Symonston, Australia, 2020.
- Mahmoudi M, Rezaei N. Nutrition and Immunity; Springer: Berlin/Heidelberg, Germany, 2019.
- Lips P, Van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 2011; 25: 585–91.
- Bikle DD. Chemistry&biology review vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 2014; 21: 319–329.
- Grant WB, Lahore H, McDonnell SL,et al. Evidence that vitamin D supplementation could reduce risk of influenza and covid-19 infections and deaths. Nutrients 2020; 12: 988.
- Jovic TH, Ali SR, Ibrahim N, et al. Could Vitamins Help in the Fight Against COVID-19. Nutrients 2020; 12: 2550
- Bieri JG, Corash L, Van Hubbard S. Medical Uses of Vitamin, E. N. Engl. J. Med. 1983; 308: 1063–71.
- Meydani SN, Leka LS, Fine BC, et al. Vitamin E and respiratory tract infections in elderly nursing home residents: A randomized controlled trial. J. Am. Med. Assoc. 2004; 292: 828–36.
- A Retrospective Study of Warning letters Issued by US FDA Over 2019-2021
Authors
1 Department of Pharmaceutical Quality Assurance, B.K. Mody Government Pharmacy College, Polytechnic Campus, Near Aji Dem, Bhavnagar Road, Rajkot – 360003 Gujarat, IN
2 L.M. College of Pharmacy, MG Science College Marg, Opp. Gujarat University, University Area, Ahmedabad – 380009 Gujarat, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 4 (2022), Pagination: 295 - 301Abstract
The United States Food and Drug Administration (US FDA) is a department of health and human services federal agency. If the FDA notices major violations of federal regulations, it sends warning letters to pharmaceutical makers, distributors, and clinical investigators. The nature of the infractions discovered, as well as the FDA's proposed corrective activities, are detailed in these warning letters. Following the completion of the corrective activities, the recipient may request a follow-up inspection. This review article examines the current state of warning letters issued by the US Food and Drug Administration (FDA) from 2019 to 2021. The main goal of this study is to examine warning letters related to drug and determine what the significant violations.
Keywords
Form no 483, Warning Letters, Violation, cGMP, Close-out letterReferences
- U.S. Food and Drug Administration. What We Do. 2021; 11(August). Available on https://www.fda.gov/about-fda/what-we- do.
- Patel AB, Bundheliya AR, et al. A Review on Metal Impurities in Pharmaceuticals. Asian Journal of Pharmaceutical Analysis. 2021 May 26; 11(3): 212-222. Doi: https://doi.org/10.52711/2231- 5675.2021.00038.
- U.S. Food and Drug Administration. FDA History. 2021; 11(August). Available on https://www.fda.gov/about-fda/fda- history.
- Prashar D. Process Validation: An Overview. Research Journal of Pharmaceutical Dosage Forms and Technology. 2011 Oct 28; 3(6): 247-250.
- Jain SK and Jain RK. A Study of Regulatory Agencies Inspected Global Drug Manufacturers. Research Journal of Pharmacy and Technology. 2021 May 11; 14(2): 1008-1016.
- Jain SK and Jain RK. Avoiding warning letters in pharmaceutical industry: A qualitative study in the Indian context. The Pharma Innovation. 2020 May 14; 9(6): 18-24. Doi: https://doi.org/10.22271/tpi.2020.v9.i6a.4767.
- U.S. Food and Drug Administration. FDA Form 483 Frequently Asked Questions. 2021; 12(August). Available on https://www.fda.gov/inspections-compliance-enforcement-and- criminal-investigations/inspection-references/fda-form-483- frequently-asked-questions.
- Bablani S and Janodia MD. Analysis of FDA Warning Letters Issue to Indian Pharmaceutical and Medical Devise Companies: A Retrospective Study. Therapeutic Innovation and Regulatory Science. 2019 Sep 09; 20(10): 1-7. Doi: https://sagepub.com/journals-permissions.
- Patel DS. FDA Warning Letter Analysis: A Tool for GMP Compliance. International Journal of Pharmaceutical Science and Research. 2012 Nov 20; 3(12): 4592-4603. ISSN: 0975-8232.
- Saini C, et al. Review of form 483s and warning letters to pharmaceutical manufacturers issued by USFDA. Journal of Generic Medicines. 2021; 0(0): 1-10. Doi: http://uk.sagepub.com/en-gb/journals-permissions.
- U.S. Food and Drug Administration. About Warning and Close- out Letters. 2021; 18(August). Available on https://www.fda.gov/inspections-compliance-enforcement-and- criminal-investigations/warning-letters/about-warning-and-close- out-letters.
- U.S. Food and Drug Administration. Warning Letters. 2021; 11(August). Available on https://www.fda.gov/.
- Jain SK and Jain RK. Review of FDA Warning Letters to Pharmaceuticals: Cause and Effect Analysis. Research Journal of Pharmacy and Technology. 2018 Apr 26; 11(7): 3219-3226. Doi: 10.5958/0974-360X.2018.00592.9.
- Jain SK and Jain RK. Evolution of GMP in Pharmaceutical Industry. Research Journal of Pharmacy and Technology. 2017 Fab 05; 10(2): 601-606. Doi: https://doi.org/10.5958/0974- 360X.2017.00118.4.
- Patil SM, Sapkale GN, et al. Quality Assurance in clinical trial. Research Journal of Pharmacology and Pharmacodynamics. 2009 oct 11; 2(1): 01-04.
- Vyas AJ, Visana NM, et al. Analytical Quality by design in stress testing or stability indicating method. Asian Journal of Pharmaceutical Analysis. 2021 Mar 08; 11(2): 170-178. Doi: https://www.doi.org/10.52711/2231-5675.2021.00029.
- Muddukrishna BS, et al. Importance of competency level and its assessment in pharmaceutical industry. Research Journal of Pharmacy and Technology. 2017 oct 04; 11(1): 139-142. Doi: https://www.doi.org/10.5958/0974-360X.2018.00027.6.
- Phadtare DG, Pawar AR, et al. A brief review on quality by design and process analytical technology. Asian Journal of Pharmaceutical Analysis. 2016 Apr 10; 6(2): 122-130. Doi: https://doi.org/10.5958/2231-5675.2016.00019.3.
- Patel AB, Asnani AH, et al. A brief review on genotoxic impurities in pharmaceuticals. Asian Journal of Pharmaceutical Research. 2021 June 05; 11(3): 187-193. Doi:https://doi.org/10.52711/2231-5691.2021.00034.
- Vyas AJ, Godhaniya JP, et al. A review on carcinogenic impurities found in marketed drugs and strategies for its determination by analytical methods. Asian Journal of Pharmaceutical Analysis. 2021 Mar 12; 11(2): 159-169. Doi: https://www.doi.org/10.52711/2231-5675.2021.00028.
- Patel AI, Maru PR, et al. Role of Vitamins, Minerals and Herbs in Strengthening immune system against the newly emerging viral disease SARS- CoV-2. Asian Journal of Research in Pharmaceutical Sciences. 2021 July 11; 11(4): 309-315. Doi: https://doi.org/10.52711/2231-5659.2021.00048.
- Ananth L, et al. A retrospective study of Warning Letters issued by US FDA over 2015-2017. International Journal of Drug Regulatory Affairs. 2018 June 03; 6(2): 48-53. Doi: https://doi.org/10.22270/ijdra.v6i2.242.
- Khoja SS, et al. A review on USFDA warning letter and violation observed in Pharmaceutical Industry. Pharma Tutor. 2016 Dec 01; 4(12): 33-36.
- U.S. Food and Drug Administration. Closeout Letters. 2021; 20(Sept). Available on https://www.fda.gov/inspections- compliance-enforcement-and-criminal-investigations/compliance- actions-and-activities/warning-letters.